Trevena Reports First Quarter 2021 Results
May 06, 2021 07:00 ET
| Source:
Trevena Inc.
Trevena Inc.
Company reaffirms YE target of 100 formulary approvals for OLINVYK®
Announces new OLINVYK clinical outcomes study to further examine potential benefit on respiratory, GI, and cognitive function
TRV027 selected for two large, multi-site COVID-19 studies led by NIH / Vanderbilt University Medical Center and REMAP-CAP
TRV045 IND filing remains on track for 1H 2021 with a lead target indication of diabetic neuropathic pain
$97.7M cash at Q1 funds operations through YE 2022
--
th
--
CHESTERBROOK, Pa., May 06, 2021 (GLOBE NEWSWIRE) --
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the first quarter ended March 31, 2021, and provided an overview of its recent operational highlights.